CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $2.22M, lower than 95% of all stocks globally
- PositionPrice-to-book is 22.29×, higher than 95% of its Biotechnology peers (median 2.56×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
503.22BKRW379.40M · vs all stocks (USD)
Revenue (TTM)
2.95BKRW2.22M · vs all stocks (USD)
52-Week Change
-3.26%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
503.22BKRW379.40M · vs all stocks (USD)
Enterprise Value
495.29BKRW373.43M · vs all stocks (USD)
Price to Book (MRQ)
22.29xvs Biotechnology peers
Enterprise to Revenue
167.84xvs Biotechnology peers
Enterprise to EBITDA
-64.89xvs Biotechnology peers
Gross Margin
76.16%vs Biotechnology peers
Operating Margin
-301.58%vs Biotechnology peers
Return on Assets (TTM)
-28.38%vs Biotechnology peers
Return on Equity (TTM)
-31.76%vs Biotechnology peers
Revenue (TTM)
2.95BKRW2.22M · vs all stocks (USD)
Revenue per Share (TTM)
296.67KRWUpdated Oct 21, 2026Quarterly Revenue Growth
107.22%vs Biotechnology peers
Gross Profit (TTM)
1.54BKRW1.16M · vs all stocks (USD)
EBITDA (TTM)
0.00KRWvs all stocks (USD)
Net Income (TTM)
-9.01BKRW-6.79M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-63.75%vs Biotechnology peers
Operating Cash Flow (TTM)
-8.07BKRW-6.09M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-9.01BKRW-6.79M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
2.95BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
1.41BKRWFY2025 · Dec 31, 2025Gross Profit
1.54BKRWFY2025 · Dec 31, 2025Operating Income
-11.37BKRW-8.57M · vs all stocks (USD)
Pre-tax Income
-9.01BKRWFY2025 · Dec 31, 2025Net Income
-9.01BKRWFY2025 · Dec 31, 2025EBIT
-8.90BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
-7.63BKRWFY2025 · Dec 31, 2025Research & Development
7.42BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
2.04BKRWFY2025 · Dec 31, 2025Other Operating Expenses
145.78MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
441.08MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
112.67MKRWFY2025 · Dec 31, 2025EPS (Basic)
-906.00KRWFY2025 · Dec 31, 2025EPS (Diluted)
-906.00KRWFY2025 · Dec 31, 2025Basic Shares Outstanding
9.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
9.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-9.01BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-9.34BKRWFY2025 · Dec 31, 2025Free Cash Flow
-10.43BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
8.79BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-9.01BKRWFY2025 · Dec 31, 2025Stock-based Compensation
350.78MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-328.41MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-42.12MKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-313.17MKRWFY2025 · Dec 31, 2025Capital Expenditures
-1.08BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-422.43MKRWFY2025 · Dec 31, 2025Purchase of Investments
-23.79BKRWFY2025 · Dec 31, 2025Sale of Investments
9.06BKRWFY2025 · Dec 31, 2025Other Investing Activity
242.89MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-15.57BKRWFY2025 · Dec 31, 2025Other Financing Charges
-7.94MKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
21.31BKRWFY2025 · Dec 31, 2025Shares Outstanding
10.94MSharesUpdated Oct 21, 2026% Held by Insiders
23.42%vs all stocks
% Held by Institutions
12.99%vs all stocks
Total Cash (MRQ)
0.00KRWvs all stocks (USD)
Total Debt (MRQ)
727.98MKRW548.87K · vs all stocks (USD)
Current Ratio (MRQ)
11.25xvs Biotechnology peers
Book Value per Share (MRQ)
2.06KKRWUpdated Oct 21, 2026Total Assets
31.75BKRW23.94M · vs all stocks (USD)
Total Current Assets
27.05BKRWFY2025 · Dec 31, 2025Total Liabilities
3.38BKRWFY2025 · Dec 31, 2025Total Non-current Assets
4.71BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
1.59BKRWFY2025 · Dec 31, 2025Total Current Liabilities
1.79BKRWFY2025 · Dec 31, 2025Cash Equivalents
8.79BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
8.79BKRWFY2025 · Dec 31, 2025Other Short-term Investments
15.11BKRWFY2025 · Dec 31, 2025Accounts Receivable
1.24BKRWFY2025 · Dec 31, 2025Inventory
494.22MKRWFY2025 · Dec 31, 2025Accounts Payable
41.06MKRWFY2025 · Dec 31, 2025Short-term Debt
280.01MKRWFY2025 · Dec 31, 2025Other Current Liabilities
-80.00KRWFY2025 · Dec 31, 2025Long-term Debt
586.55MKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
130.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
1.09BKRWFY2025 · Dec 31, 2025Retained Earnings
-72.91BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
28.37BKRW21.39M · vs all stocks (USD)
52-Week Low
15.50KKRWUpdated Oct 21, 202652-Week High
120.10KKRWUpdated Oct 21, 202652-Week Change
-3.26%vs all stocks
50-Day MA
37.47KKRWUpdated Oct 21, 2026200-Day MA
52.21KKRWUpdated Oct 21, 2026Avg 10-Day Volume
187.14KSharesUpdated Oct 21, 2026Avg 30-Day Volume
152.30KSharesUpdated Oct 21, 2026Diluted EPS (TTM)
-906.00KRWUpdated Oct 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 22.29×, higher than 95% of its Biotechnology peers (median 2.56×)Significant
Price-to-book: 22.29Industry median: 2.56Industry P95: 15.40Peers compared: 255
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $2.22M, lower than 95% of all stocks globallySignificant
Revenue (USD): 2,224,874.392Global P5: 36,021,613.518
Companies that share the same coordination system — how they create, deliver, or capture value.
Avacta Group Plc
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
CapsoVision, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Hinova Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Eikon Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Tomocube Inc.
Tier 1ProductionApproval-Gated PipelineSenseMaking
ClearPoint Neuro Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shanghai Model Organisms Center Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Aclaris Therapeutics Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Microvision Inc.
3 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Lunit Inc.
2 interpretationsHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBCUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated